Trane Technologies (TT)
(Delayed Data from NYSE)
$331.98 USD
-0.94 (-0.28%)
Updated May 10, 2024 04:00 PM ET
After-Market: $331.99 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
TT 331.98 -0.94(-0.28%)
Will TT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TT
Is Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) a Strong ETF Right Now?
Avis Budget (CAR) Gains 28% Despite Earnings Miss in Q1
TT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Automatic Data Processing (ADP) Q3 Earnings Beat Estimates
Are Business Services Stocks Lagging CompoSecure (CMPO) This Year?
Trane Technologies plc (TT) Hits Fresh High: Is There Still Room to Run?
Other News for TT
Barclays spotlights 44 stocks to watch if inflation remains sticky
Range Energy and Thermo King Collaborate to Advance the Commercial Adoption of Electric Refrigerated Trailers in the Americas
Trane Technologies and the U.S. Department of Energy Partner To Advance Building Decarbonization in New Heat Pump Technology Challenge
Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma
Trane Technologies and the U.S. Department of Energy Partner to Advance Building Decarbonization in New Heat Pump Technology Challenge